Dr. Vishalkumar Vanani
MBBS, MD, Medicine,
DNB Cardiology (Jaslok Hospital,Mumbai),
Dr. Vishal Heart Care, Comprehensive Cardiovascular Clinic.

This study evaluated the efficacy and safety of angiotensin receptor-neprilysin inhibitor sacubitril-valsartan (LCZ696) in Patient with chronic heart failure (CHF) along with end-stage renal disease (ESRD) requiring dialysis. The hypothesis was that  LCZ696 treatment could reduce rehospitalization rates for HF, delay rehospitalizations, and prolong survival time. The study analyzed clinical data from 65 CHF patients admitted to the Second Hospital of Tianjin Medical University from August 2019 to October 2021. Results showed that the LCZ696 group had significantly longer free-event survival time than the control group over a 1-year follow-up. The study concluded that LCZ696 treatment is effective and safe in CHF patients with ESRD on dialysis.

Click Here to view the article:

John Wiley & Sons, Inc.